B-CELL NON HODGKIN LYMPHOMA
Clinical trials for B-CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough lymphoma: early trial launches for drug SAR448501
Disease control Recruiting nowThis early-phase study tests a new drug, SAR448501, in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. Partici…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 01, 2026 15:27 UTC
-
New drug IKS03 aims to shrink Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase trial tests a new drug called IKS03 in about 140 adults with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is designed to seek out and attack cancer cells while sparing healthy ones. The main goals are to find the safest d…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Engineered immune cells take on tough blood cancers in new mayo clinic trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. It is for people with certain types of B-cell blood cancers (like lymphoma or leukemia) that have return…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Double attack on tough lymphoma: stem cell transplant plus immune cells
Disease control Recruiting nowThis study tests whether giving a special immune cell treatment (CD19 CAR-T) after a stem cell transplant can help people with hard-to-treat B-cell lymphoma. It includes 16 adults whose lymphoma has come back or not responded to standard therapy. The goal is to see if this combin…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
Experimental combo therapy aims to stop lymphoma return after transplant
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug surovatamig enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called surovatamig (AZD0486) in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior treatments. The goal is to see how well the drug shrinks tumors and to check for side effects. About 240 pa…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Personalized support for seniors after CAR-T: a new study aims to speed recovery
Symptom relief Recruiting nowThis study tests whether a special health check-up for older adults (called a geriatric assessment) can help people aged 60 and older recover faster after CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. The check-up looks at physical function, thinking skills, …
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated May 01, 2026 15:38 UTC
-
CAR t patients monitored for years in new Follow-Up study
Knowledge-focused Recruiting nowThis study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma and leukemia. Researchers will track late side effects, infections, and disease relapse to understand long-term safety. Participants do not receive new treatment …
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: NA • Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC